Trial Profile
A Phase I Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Sep 2021
Price :
$35
*
At a glance
- Drugs Bisthianostat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Shanghai Theorion Pharmaceutical
- 17 Jun 2021 Results (n=15; data cut off date:Dec 29, 2020) assessing the safety, tolerability, pharmacokinetics, and efficacy of single-agent bisthianostat in patients with refractory or recurrent multiple myeloma, presented at the 26th Congress of the European Haematology Association.
- 16 Aug 2018 New trial record